Pinealon-B
Extended Pineal Cognitive Tripeptide
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
The published record for the underlying peptide (Pinealon, Glu-Asp-Arg / EDR) is animal and in-vitro only, and comes almost entirely from Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. Foundational work (Khavinson et al., Rejuvenation Research 2011) reported dose-dependent suppression of reactive oxygen species and reduced necrotic death in cerebellar granule and PC12 cells, and a later mechanistic review (Khavinson et al., Molecules 2020) associates the peptide with SOD2/GPX1 upregulation, caspase-3 reduction and gene-expression modulation relevant to Alzheimer models. No completed randomized controlled human trial supports the cognitive or circadian claims, and the specific marketed variant Pinealon-B has no independent published data of its own, so grade 1 (animal / anecdotal) is honest.
- FDA
- Unapproved; sold for research use only / not for human consumption, no FDA-approved human indication and not an established compounding bulk substance
- WADA
- Prohibited (S0, Non-Approved Substances) at all times in sport, as an unapproved synthetic peptide
Reference only. Not medical advice.
What can go wrong
Earliest-stage, single-source preclinical peptide sold as a research chemical; no human safety data, purity and identity of the marketed 'Pinealon-B' variant are unverified.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Pinealon-B. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
A research variant in the pineal-bioregulator family targeting cognitive protection and circadian regulation. Minimal published data.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Pinealon-B is a brain-directed peptide bioregulator in the Khavinson family, promoted for neuroprotection and cognitive support, closely related in intent to Pinealon. Its proposed mechanism in human neural tissue is unproven.
Pinealon-B is presented as a brain-targeted short peptide in the Khavinson style, a naming variant within the cluster of brain and cortex bioregulators rather than a clearly distinct molecule.
- Type
- Brain-labeled short peptide
- Target
- Brain and cognition
- Generation
- Second (defined)
- Use
- Pulsed courses
- Evidence
- Preclinical and Russian
- Western RCT
- None
A Brain-Labeled Variant Within The Same Peptide System
Pinealon-B is best understood as another brain-labeled entry in a family that already includes Pinealon and Cortagen, and it inherits their situation entirely. The mechanism is the contested gene-regulation proposal, the cognitive claims are preclinical and tied to the originating lineage, and there are no independent human trials. The existence of multiple closely named brain peptides is itself the main point: the system tends to spawn variants and naming conventions around the same unverified core, and Pinealon-B adds little that is independently distinct.
Safety in detail
No completed human trials establish safety or efficacy for the parent peptide or this variant. Vendors label it 'for research use only, not for human consumption,' and marketing it with cognitive, neuroprotective or anti-aging claims is associated with unapproved-drug enforcement risk. Any benefit language for 'Pinealon-B' is attributable to the seller, not to peer-reviewed human evidence.
- Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
- Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
- Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
- Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.
Children and teenagers
Pinealon-B has no validated pediatric use and is an unapproved injected peptide. There is no appropriate pediatric use.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Pinealon-B reaches users only through the bioregulator gray market and longevity vendors, with no approved product.
How we got here
The entry's real chemical basis is Pinealon, a synthetic Glu-Asp-Arg (EDR) tripeptide developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, part of the same Soviet and Russian peptide-bioregulator program that produced Epitalon and the pineal-extract drug Epithalamin. It sits in the pineal branch of that family, proposed to cross the blood-brain barrier and modulate neuronal gene expression. 'Pinealon-B' / 'Extended Pineal Cognitive Tripeptide' is a proprietary variant name applied within this library and by sellers rather than a distinct peer-reviewed molecule, so any variant-specific cognitive or circadian benefit should be read as seller framing layered on top of Pinealon's preclinical, single-network evidence base.
Pinealon-B appears as a brain-labeled variant within the Khavinson bioregulator program’s cluster of neurological peptides.
The numbers behind the grade
- Type
- Brain peptide
- Target
- Brain / cognition
- Russia
- Bioregulator line
- FDA
- Not approved
- Evidence
- Single-tradition
- Western RCTs
- None
The people taking it
A brain-directed cognitive bioregulator, closely related to Pinealon, with a small longevity following.
Pinealon-B’s users are cognitive-longevity enthusiasts and the bioregulator-protocol community.
Used as a neuroprotective and cognitive bioregulator within Russian-tradition protocols; not independently validated.
Set against the alternatives
Pinealon-B overlaps with the core brain peptides Pinealon and Cortagen and the brain extract Cortexin, sharing the family’s framing. It is more a naming variant than an independently distinct compound, with preclinical single-lineage support.
What we do not know
- Whether independent, Western randomized trials confirm any of the claimed clinical effects.
- Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
- Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
- Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.
Legal status
Not FDA-approved for any indication in the United States. Several related bioregulators are registered pharmaceuticals in Russia, where they are used clinically, but that approval does not carry to the US or EU. The first formal FDA advisory-committee evaluation of a Khavinson peptide (Epitalon) is scheduled for July 2026. Internationally it is sold as a Cytogen or Cytomax supplement and as a research chemical.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.
Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Pinealon-B.
- Timeline. We have not built the dated record of research and regulatory events.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
Sources
Pinealon (Glu-Asp-Arg / EDR) suppresses reactive oxygen species and reduces cell death in cerebellar granule and PC12 neurons, with delayed ERK1/2 activation; foundational preclinical antioxidant/neuroprotection paper.
EDR (Pinealon) proposed to regulate gene expression and protein synthesis (SOD2, GPX1, caspase-3, MAPK/ERK) relevant to Alzheimer pathogenesis; combines in-vitro, rodent and limited elderly-patient observations, no controlled human trial.
Independent research-guide summary confirming Pinealon = synthetic Glu-Asp-Arg (EDR) tripeptide from the Khavinson bioregulator program, blood-brain-barrier permeable, proposed DNA/chromatin interaction and circadian involvement.
PeptideDeck, 'Pinealon (Glu-Asp-Arg / EDR Tripeptide) Complete Research Guide'
Confirms Pinealon is a Khavinson-group tripeptide (EDR) still in preclinical stage with no completed human RCTs, and situates it in the ultrashort peptide bioregulator theory.
Superpower, 'Pinealon (EDR): A Khavinson-Group Tripeptide' guide
States no peer-reviewed randomized controlled human trial of Pinealon exists; all human-facing benefit claims are extrapolated from rodent learning tasks and the Khavinson framework.
The Peptide Catalog, 'Pinealon Benefits: What Preclinical Data Shows (2026)'
Independent benefits/safety and buying overview confirming Pinealon is sold research-grade, unapproved, with an in-vitro and rodent evidence base and no FDA-approved indication.
Innerbody, 'Pinealon Peptide: Benefits, Safety & Buying Advice (2026)'
Regulatory status: Pinealon has no FDA approval for any human indication, is not an established compounding bulk substance, is sold 'for research use only / not for human consumption,' and is not a DEA controlled substance.
As a non-approved synthetic peptide, Pinealon falls under WADA Prohibited List category S0 (Non-Approved Substances), prohibited at all times in sport, rather than being outside the list.
Corroborates Pinealon's preclinical antioxidant, anti-apoptotic and proliferative effects and cellular-aging mechanisms, again sourced to the Khavinson research lineage.
BiotechPeptides, 'Pinealon Peptide: Implications for Neuroprotection, Cellular Aging Mechanisms'
The studies that matter
Khavinson group studies2000s-2010s
Reported neural and cognitive effects within the bioregulator research program.
Independent replicationnone notable
No independent Western trials of this brain-peptide variant exist.